4-pentafluorosulfanylbenzothioamide | 1020113-66-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-pentafluorosulfanylbenzothioamide
• 英文别名: 4-Pentafluorosulfanyl-thiobenzamide；4-(pentafluoro-λ6-sulfanyl)benzenecarbothioamide
• CAS: 1020113-66-9
• 化学式: C₇H₆F₅NS₂
• 分子量: 263.255
• InChiKey: PZFPLMURBZLGPU-UHFFFAOYSA-N

物化性质

• 熔点：
  136-137 °C

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  59.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-溴-2',5'-二甲氧基苯乙酮 、 4-pentafluorosulfanylbenzothioamide 以 乙醇 为溶剂， 反应 2.0h， 以91%的产率得到4-(2′,5′-dimethoxy)-2-(4″-pentafluorosulfanylphenyl)-1,3-thiazole
  参考文献：
  名称：

  2,4-Diaryl-1,3-Chalcogen Azoles Bearing Pentafluorosulfanyl SF₅Groups: A Synthetic and Structural Study

  摘要：

  A series of new 2,4-diaryl-1,3-chalcogen azoles having pentafluorosulfanyl SF5 functional groups has been prepared by means of the two-component cyclization of the selenoamide or thioamide with alpha-bromoketones. The selenoamides or thioamides were obtained from the reaction of Woollins' reagent or Lawesson's reagent with 4-pentafluorosulfanylbenzonitrile, followed by hydrolysis with water. All new compounds were characterised by H-1, C-13, Se-77, F-19 NMR spectroscopy and accurate mass measurement. X-ray crystal structure analysis of the selenoamide, thioamide and 2,4-diarylpentafluorosulfanyl-1,3-chalcogen azoles reveal that the selenoamide and thioamide have very similar structural features along with similar intermolecular interactions such as the pi-pi stacking and the weak N-H center dot center dot center dot E (E = S or Se) hydrogen bonding. The 2,4-diarylpentafluorosulfanyl-1,3-chalcogen azoles show the newly formed five-membered N(1)-C(2)-E(3)-C(4)-C(5) ring is either perfectly planar (and coplanar with two peripheral aryl ring planes) or near-planar. The pi-pi intermolecular interactions and the weak C-H center dot center dot center dot pi and C-H center dot center dot center dot X (X = Br, F, O) hydrogen bonding are discussed in the cases of 2,4-diarylpentafluorosulfanyl-1,3-chalcogen azoles.

  DOI：

  10.1021/jo500316v
• 作为产物：
  描述：

  五氟化(4-氰苯基)硫 在 劳森试剂 、 水 作用下， 以 甲苯 为溶剂， 反应 11.0h， 以61%的产率得到4-pentafluorosulfanylbenzothioamide
  参考文献：
  名称：

  2,4-Diaryl-1,3-Chalcogen Azoles Bearing Pentafluorosulfanyl SF₅Groups: A Synthetic and Structural Study

  摘要：

  A series of new 2,4-diaryl-1,3-chalcogen azoles having pentafluorosulfanyl SF5 functional groups has been prepared by means of the two-component cyclization of the selenoamide or thioamide with alpha-bromoketones. The selenoamides or thioamides were obtained from the reaction of Woollins' reagent or Lawesson's reagent with 4-pentafluorosulfanylbenzonitrile, followed by hydrolysis with water. All new compounds were characterised by H-1, C-13, Se-77, F-19 NMR spectroscopy and accurate mass measurement. X-ray crystal structure analysis of the selenoamide, thioamide and 2,4-diarylpentafluorosulfanyl-1,3-chalcogen azoles reveal that the selenoamide and thioamide have very similar structural features along with similar intermolecular interactions such as the pi-pi stacking and the weak N-H center dot center dot center dot E (E = S or Se) hydrogen bonding. The 2,4-diarylpentafluorosulfanyl-1,3-chalcogen azoles show the newly formed five-membered N(1)-C(2)-E(3)-C(4)-C(5) ring is either perfectly planar (and coplanar with two peripheral aryl ring planes) or near-planar. The pi-pi intermolecular interactions and the weak C-H center dot center dot center dot pi and C-H center dot center dot center dot X (X = Br, F, O) hydrogen bonding are discussed in the cases of 2,4-diarylpentafluorosulfanyl-1,3-chalcogen azoles.

  DOI：

  10.1021/jo500316v

文献信息

• OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS
  申请人：KEIL Stefanie

  公开号：US20080255212A1

  公开（公告）日：2008-10-16

  The invention relates to oxadiazolones and to their physiologically acceptable salts and physiologically functional derivatives showing peroxisome proliferator activator receptor (PPAR) delta agonist activity comprising compounds of formula I, in which the R1-R7 substituents as well as the U, V, W, X Y and z radicals are as defined herein, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved; neurodegenerative diseases and/or de-myelinating disorders of the central and peripheral nervous systems and/or neurological diseases involving neuro-inflammatory processes and/or other peripheral neuropathies.

  本发明涉及氧化二氮杂环酮及其生理上可接受的盐和生理上功能衍生物，其显示过氧化物酶体增殖物激活受体（PPAR）δ激动剂活性，包括式I中的化合物，其中R1-R7取代基以及U、V、W、X、Y和z基团的定义如本文所述，以及它们的生理上可接受的盐和制备方法。这些化合物适用于治疗和/或预防脂肪酸代谢和葡萄糖利用障碍以及胰岛素抵抗涉及的疾病；中枢神经系统和/或周围神经系统的神经退行性疾病和/或去髓鞘疾病以及涉及神经炎症过程和/或其他周围神经病的神经疾病。
• METHODS FOR THE TREATMENT OF METABOLIC AND GLUCOSE UTILIZATION DISORDERS THROUGH THE ADMINISTRATION OF OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS
  申请人：KEIL Stefanie

  公开号：US20080262052A1

  公开（公告）日：2008-10-23

  The invention relates to oxadiazolones and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta agonist activity. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved; neurodegenerative diseases and/or de-myelinating disorders of the central and peripheral nervous systems and/or neurological diseases involving neuro-inflammatory processes and/or other peripheral neuropathies.

  本发明涉及氧化二唑酮及其生理上可接受的盐和生理上功能衍生物，显示PPARδ激动剂活性。所描述的化合物为公式I中的基团，其定义如上，并且它们的生理上可接受的盐和制备过程。该化合物适用于治疗和/或预防脂肪酸代谢紊乱和葡萄糖利用紊乱以及胰岛素抵抗涉及的疾病；中央和周围神经系统的神经退行性疾病和/或去髓鞘疾病和/或涉及神经炎症过程和/或其他周围神经病变的神经疾病。
• OXADIAZOLONES AND DERIVATIVES THEREOF AS PPAR DELTA AGONISTS
  申请人：KEIL Stefanie

  公开号：US20070179191A1

  公开（公告）日：2007-08-02

  The invention relates to oxadiazolones and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta agonist activity. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved; neurodegenerative diseases and/or demyelinating disorders of the central and peripheral nervous systems and/or neurological diseases involving neuroinflammatory processes and/or other peripheral neuropathies.

  本发明涉及氧化二氮杂环酮及其生理上可接受的盐和生理功能衍生物，其具有PPARdelta激动剂活性。所描述的化合物为公式I中的基团所定义的化合物及其生理上可接受的盐和制备方法。这些化合物适用于治疗和/或预防脂肪酸代谢紊乱和葡萄糖利用紊乱以及胰岛素抵抗相关的疾病；中枢和周围神经系统的神经退行性疾病和/或脱髓鞘性疾病以及涉及神经炎性过程和/或其他周围神经病变的神经疾病。
• Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：US07709509B2

  公开（公告）日：2010-05-04

  The invention relates to oxadiazolones and to their physiologically acceptable salts and physiologically functional derivatives showing peroxisome proliferator activator receptor (PPAR) delta agonist activity comprising compounds of formula I, in which the R1-R7 substituents as well as the U, V, W, X Y and z radicals are as defined herein, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved; neurodegenerative diseases and/or demyelinating disorders of the central and peripheral nervous systems and/or neurological diseases involving neuro-inflammatory processes and/or other peripheral neuropathies.

  本发明涉及氧化二唑酮及其生理上可接受的盐和生理上功能衍生物，其显示过氧化物酶体增殖剂激活受体（PPAR）δ激动剂活性，包括式I的化合物，其中R1-R7取代基以及U、V、W、X、Y和z基团如此定义，并且其生理上可接受的盐和制备过程。这些化合物适用于治疗和/或预防脂肪酸代谢紊乱和葡萄糖利用紊乱以及胰岛素抵抗涉及的紊乱；中枢和周围神经系统的神经退行性疾病和/或脱髓鞘疾病和/或涉及神经炎症过程和/或其他周围神经病。
• Oxadiazolones, processes for their preparation and their use as pharmaceuticals
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：EP2083006A1

  公开（公告）日：2009-07-29

  The invention relates to oxadiazolones and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta agonist activity. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved; neurodegenerative diseases and/or demyelinating disorders of the central and peripheral nervous systems and/or neurological diseases involving neuroinflammatory processes and/or other peripheral neuropathies.

  本发明涉及恶二唑酮及其生理上可接受的盐类和生理功能衍生物，它们具有 PPARdelta 激动剂活性。 所述的是式 I 的化合物、 的化合物、它们的生理学上可接受的盐及其制备工艺。这些化合物适用于治疗和/或预防脂肪酸代谢紊乱、葡萄糖利用紊乱以及涉及胰岛素抵抗的紊乱；神经退行性疾病和/或中枢和周围神经系统的脱髓鞘疾病和/或涉及神经炎症过程和/或其他周围神经病的神经系统疾病。